Article
Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
The Journal of infectious diseases - 1 May 2004
Boivin Guy, Goyette Nathalie, Gilbert Christian, Roberts Noel, Macey Katherine, Paya Carlos, Pescovitz Mark D, Humar Atul, Dominguez Ed, Washburn Kenneth, Blumberg Emily, Alexander Barbara, Freeman Richard, Heaton Nigel, Covington Emma
Abstract excerpt
We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations in 301 high-risk solid-organ transplant (SOT) recipients after oral prophylaxis, for 100 days, with either valganciclovir or ganciclovir. For patients treated with ganciclovir, the incidence of CMV UL97 mutations was 1.9% (2/103) at the end of prophylaxis and 6.1% (2/33) for patients with suspected CMV disease up to 1 year...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.